PharmaCyte Biotech, Inc.'s Form 4 filing
Q/C Technologies, Inc. (QCLS) · filed Nov 18, 2025
- Accession no.
- 0001683168-25-008517
- Filed
- Nov 18, 2025
- Trade date
- Sep 4-Nov 14, 2025
- Filing delay
- 75 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 75 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| PharmaCyte Biotech, Inc.CIK 0001157075 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | Common stock, par value $0.001 per share | PPurchaseAcquired | +889,865 | – | – | 889,865 | Direct | |
| Nov 14, 2025 | Common stock, par value $0.001 per share | PPurchaseAcquired | +889,865 | – | – | 889,865 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.